ClinicalTrials.gg
RecruitingNCT05844059LUTSIUpdated May 6, 2023

Lower Urinary Tract Symptoms After Intravesical Therapy

An observational study in Chemotherapy Effect, Chemotherapeutic Toxicity and Lower Urinary Tract Symptoms, sponsored by Ludwig-Maximilians - University of Munich. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-05-06.

Primary conditionUrinary Bladder, OveractiveRegistry: Lower Urinary Tract SymptomsReclassifiedWhy we changed it
Registry
Lower Urinary Tract Symptoms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Urinary Bladder, Overactive
Why
  1. The study's listed conditions name Urinary Bladder, Overactive, a narrower term within Lower Urinary Tract Symptoms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ludwig-Maximilians - University of Munich · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 48 studies in Urinary Bladder, Overactive with a site in Germany — 1 open to participants now, 1 under way, none of them phase 3. Urinary Bladder, Overactive · Germany.

Started
2023
the only one that year
Observational
4 of 48
1 open now
Registered
48th of 48
by date
Lead sponsor
2 of 48
Ludwig-Maximilians - University of Munich

Among the 48 studies in Urinary Bladder, Overactive with a site in Germany, this one is the only one that started in 2023, is one of 4 observational ones, and was the 48th registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

1 of the 48 studies in Urinary Bladder, Overactive with a site in Germany is open now.

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Urinary Bladder, Overactive with a site in Germany, or all of them as a file.
02

Study summary

With this prospective, observational study, we would like to investigate the effect of instillation therapy using BCG or mitomycin C on short- and long-term irritative and obstructive lower urinary tract symptoms using validated questionnaires. The study will objectify the lower urinary tract symptoms and thereby provide better recommendations for therapy with mitomycin C or BCG.

03

Conditions studied

  • Chemotherapy Effect
  • Chemotherapeutic Toxicity
  • Lower Urinary Tract Symptoms
  • Overactive Bladder

Browse trials for

04

In context

Urinary Bladder, Overactive Reclassified

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

This study's planned enrollment of 60 is below the median of 120 across 169 observational studies indexed under Urinary Bladder, Overactive.

Browse Urinary Bladder, Overactive studies →

Lead sponsor

Ludwig-Maximilians - University of Munich is the lead sponsor of 223 studies on the registry; 29 are open to participants now.

Compared within Urinary Bladder, Overactive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lower Urinary Tract Symptoms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with urinary bladder carcinoma requiring instillation therapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Urinary bladder carcinoma requiring instillation therapy
  • Complete resection of the tumor
  • No intravesical chemotherapy in the last 3 months

Exclusion criteria

Exclusion Criteria:

  • Patients who are unable to complete the questionnaires
  • Patients who are not willing to participate
  • Patients with for instillation therapy (allergic reactions, )
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients undergoing instillation therapy with BCG

    All patients that undergo therapy with BCG after diagnosis of non-muscle-invasive bladder cancer

    Other: Validated questionnaires

  • Patients undergoing instillation therapy with Mitomycin C

    All patients that undergo therapy with Mitomycin C after diagnosis of non-muscle-invasive bladder cancer

    Other: Validated questionnaires

Interventions

  • OtherValidated questionnaires

    BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS

07

What researchers measure

Primary outcomes

  1. Effect of instillation therapy on quality of life

    Quality of life will be measured with validated questionnaires such as the ICIQ-OABqol

    Time frame: During the study period approximately 12 months

  2. Effect of instillation therapy on sexuality

    Sexuality will be measured with validated questionnaires such as the IIEF-EF (men) and the FSFI (women)

    Time frame: During the study period approximately 12 months

  3. Effect of instillation therapy on lower urinary tract symptoms

    Lower urinary tract symptoms will be measured with validated questionnaires such as the BPIC-SS, the ICIQ-MLUTS (men) and the ICIQ-FLUTS (women)

    Time frame: During the study period approximately 12 months

Secondary outcomes

  1. Complications during instillation therapy

    The frequency of all complications will be measured and will be subsequently classified based on the Clavien-Dindo classification

    Time frame: During the study period approximately 12 months

  2. Discontinuation rate of instillation therapy

    Time frame: During the study period approximately 12 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Apr 2025, 24 months after the start.

Of 46 non-industry observational studies under Urinary Bladder, Overactive, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 24 months is below that.

Counting every sponsor, half of 59 studies reached it within 32 months; a quarter within 17 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2023
First posted
May 6, 2023
StartActual
Apr 21, 2023
Primary completionEst.
Apr 24, 2025
CompletionEst.
Apr 24, 2026
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05844059
Responsible party
Benedikt Ebner (Dr. med., Ludwig-Maximilians - University of Munich) — Principal investigator
First posted
May 6, 2023
Start date
Apr 21, 2023
Primary completion
Apr 24, 2025 (estimated)
Completion
Apr 24, 2026 (estimated)
Last update
May 6, 2023

Study contacts

Nikolaos Pyrgidis, Urologist
Contact
nikolaos.pyrgidis@med.uni-muenchen.de
004989440073531

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion